FDA to re­view Takeda's BLA re­sub­mis­sion for sub­cu­ta­neous UC drug En­tyvio af­ter 2019 re­jec­tion

Take­da has re­filed a bi­o­log­ics li­cense ap­pli­ca­tion for its sub­cu­ta­neous ver­sion of the block­buster ul­cer­a­tive col­i­tis drug En­tyvio fol­low­ing an FDA re­jec­tion in 2019, the …

Endpoints News

Sign up to read this article for free.

Get free access to a limited number of articles, plus choose newsletters to get straight to your inbox.